多西他赛联合顺铂在合并人类免疫缺陷病毒感染的晚期非小细胞肺癌患者中的疗效分析

Clinical effect of docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer patients with human immunodeficiency virus infection

目的探讨多西他赛联合顺铂在合并人类免疫缺陷病毒(HIV)感染的晚期非小细胞肺癌患者中的临床疗效和不良反应。方法回顾性分析2016年8月至2019年10月郑州市第六人民医院收治的43例晚期非小细胞肺癌患者的临床病理资料。根据是否合并HIV感染分为2组,其中合并HIV感染的21例患者作为观察组,未合并HIV感染的22例患者作为对照组。2组患者均行多西他赛联合顺铂化疗2周期。比较观察2组患者的近期疗效及不良反应。结果观察组总有效率和疾病控制率分别为38.09%、61.90%,对照组分别为40.90%、68.18%,比较差异均无统计学意义(χ^2=0.036,P=0.850;χ^2=0.186,P=0.666)。观察组白细胞减少、血小板减少、腹泻、口腔黏膜炎发生率分别为90.48%、47.62%、42.86%、38.10%,均高于对照组的59.09%、18.18%、9.09%、4.54%,比较差异均有统计学意义(χ^2=5.559,P=0.018;χ^2=4.240,P=0.039;χ^2=6.435,P=0.011;χ^2=7.307,P=0.007)。观察组血红蛋白减少、恶心呕吐、肝肾功能异常、脱发发生率分别为52.38%、71.43%、57.14%、19.05%,对照组分别为45.45%、77.27%、50.00%、22.73%,比较差异均无统计学意义(χ^2=0.206,P=0.650;χ^2=0.193,P=0.661;χ^2=0.220,P=0.639;χ^2=0.088,P=0.767)。结论多西他赛联合顺铂在合并HIV感染的晚期非小细胞肺癌患者中的近期疗效与未合并HIV感染的晚期非小细胞肺癌患者相当,但化疗相关骨髓抑制、腹泻、口腔黏膜炎等较为严重,化疗方案需要根据患者具体情况进行调整。

Objective To explore the clinical effect of docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer patients with human immunodeficiency virus(HIV).Methods The clinical and pathological data of 43 patients with advanced non-small cell lung cancer treated in the Sixth People’s Hospital of Zhengzhou City from August 2016 to October 2019 were retrospectively analyzed,21 advanced non-small cell lung cancer patients with HIV infection were included as the observation group,and 22 advanced non-small cell lung cancer patients with non-HIV infection were included as the control group.All the patients received 2 cycles of docetaxel combined with cisplatin chemotherapy,and the short-term efficacy and side effects were compared between the two groups.Results There were no significant differences in the overall response rate and the disease control rate between the observation group(38.09%and 61.90%)and the control group(40.90%and 68.18%;χ^2=0.036,P=0.850;χ^2=0.186,P=0.666).The incidences of leukopenia,thrombocytopenia,diarrhea,oral mucositis in the observation group(90.48%,47.62%,42.86%,38.10%)were higher than those in the control group(59.09%,18.18%,9.09%,4.54%;χ^2=5.559,P=0.018;χ^2=4.240,P=0.039;χ^2=6.435,P=0.011;χ^2=7.307,P=0.007).The incidences of hemoglobin reduction,nausea and vomiting,abnormal liver and kidney function,hair loss in the observation group were respectively 52.38%,71.43%,57.14%,19.05%,and were 45.45%,77.27%,50.00%,22.73%in the control group(χ^2=0.206,P=0.650;χ^2=0.193,P=0.661;χ^2=0.220,P=0.639;χ^2=0.088,P=0.767).Conclusion The short-term efficacy of docetaxel combined with cisplatin in the advanced non-small cell lung cancer patients with HIV infection is comparable to that of the advanced non-small cell lung cancer patients with non-HIV infection,but the side effects of bone marrow suppression,diarrhea and oral mucositis after chemotherapy are obvious.